Overview

  • Product name

    Anti-TACI antibody [3H4A4]
    See all TACI primary antibodies
  • Description

    Mouse monoclonal [3H4A4] to TACI
  • Host species

    Mouse
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment corresponding to Human TACI aa 1-165 (extracellular). (Expressed in E.coli).
    Database link: O14836

  • Positive control

    • WB: Human TACI (aa 1-165) recombinant protein; TACI (aa 1-165)-hIgGFc transfected HEK-293 cell lysate.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservative: 0.05% Sodium azide
    Constituent: PBS
  • Concentration information loading...
  • Purity

    Protein G purified
  • Purification notes

    Purified from tissue culture supernatant.
  • Clonality

    Monoclonal
  • Clone number

    3H4A4
  • Isotype

    IgG2a
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab233774 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/2000. Predicted molecular weight: 32 kDa.

Target

  • Function

    Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
  • Tissue specificity

    Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
  • Involvement in disease

    Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.
  • Sequence similarities

    Contains 2 TNFR-Cys repeats.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • CD 267 antibody
    • CD267 antibody
    • CD267 antigen antibody
    • CVID antibody
    • CVID2 antibody
    • FLJ39942 antibody
    • MGC133214 antibody
    • MGC39952 antibody
    • OTTHUMP00000065442 antibody
    • TNFRSF 13B antibody
    • TNFRSF 14B antibody
    • TNFRSF13B antibody
    • TNFRSF13B protein antibody
    • TNFRSF14B antibody
    • TR13B_HUMAN antibody
    • Transmembrane activator and CAML interactor antibody
    • Tumor necrosis factor receptor 13B antibody
    • Tumor necrosis factor receptor superfamily member 13B antibody
    see all

Images

  • All lanes : Anti-TACI antibody [3H4A4] (ab233774) at 1/500 dilution

    Lane 1 : HEK-293 (human epithelial cell line from embryonic kidney) cell lysate.
    Lane 2 : TACI (aa 1-165)-hIgGFc transfected HEK-293 cell lysate.

    Predicted band size: 32 kDa

  • Anti-TACI antibody [3H4A4] (ab233774) at 1/500 dilution + Human TACI (aa 1-165) recombinant protein

    Predicted band size: 32 kDa



    Expected MW is 44.5 kDa.

References

ab233774 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab233774.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up